BCI FLUVOXAMINE TABLETS 100.0 MG
FLUVOXAMINE MALEATE : 100.0 MG · DIN 02257688 · BAKER CUMMINS INC
Health Canada status: CANCELLED POST MARKET
What is BCI FLUVOXAMINE TABLETS?
BCI FLUVOXAMINE TABLETS 100.0 MG contains FLUVOXAMINE MALEATE : 100.0 MG. It is listed in the Health Canada Drug Product Database under DIN 02257688, held by BAKER CUMMINS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 03-Oct-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BCI FLUVOXAMINE TABLETS used for?
BCI Fluvoxamine Tablets (fluvoxamine maleate) may be indicated for the symptomatic relief of depressive illness. BCI Fluvoxamine Tablets (fluvoxamine maleate) has been shown to significantly reduce the symptoms of obsessive-compulsive disorder.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02257688 |
|---|---|
| Brand name | BCI FLUVOXAMINE TABLETS |
| Generic / active ingredient | FLUVOXAMINE MALEATE : 100.0 MG |
| Manufacturer | BAKER CUMMINS INC |
| Strength | 100.0 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AB08 FLUVOXAMINE |
| AHFS class | 28:16.04.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 03-Oct-2006 |
| Original market date | 2005-07-04 00:00:00 |
How is it administered?
Initial: 50 mg at bedtime, increase to 100 mg after a few days. Range: 100-300 mg/day. Doses >150 mg should be divided. Swallow whole with water.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
null
Contraindications
Hypersensitivity; concomitant MAOIs (within 2 weeks), thioridazine, mesoridazine, terfenadine, astemizole, or cisapride.
Warnings and precautions
Potential for behavioral/emotional changes including self-harm; do not discontinue abruptly; risk of QTc prolongation with certain interactions; seizures; serotonin syndrome; sedation.
What can be used instead?
Other Canadian products sharing ATC code N06AB08 FLUVOXAMINE. 6 of 34 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FLUVOXAMINE | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02231330 |
| APO-FLUVOXAMINE | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02231329 |
| LUVOX | 100 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 01919369 |
| LUVOX | 50 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 01919342 |
| TEVA-FLUVOXAMINE | 100 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02255537 |
| TEVA-FLUVOXAMINE | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02255529 |
| AVA-FLUVOXAMINE | 100 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363771 |
| AVA-FLUVOXAMINE | 50 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363763 |
| BCI FLUVOXAMINE TABLETS | 50.0 MG | TABLET | BAKER CUMMINS INC | CANCELLED POST MARKET | DIN 02257661 |
| DOM-FLUVOXAMINE | 100 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02241348 |
Who else supplies FLUVOXAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FLUVOXAMINE appears in 127 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.